Management strategy of early-stage breast cancer patients with a positive sentinel lymph node: With or without axillary lymph node dissection

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 3, 2011, Pages 293-301

  Chen, Jia Jian ^a   Wu, Jiong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast carcinoma; Node metastasis; Prognosis; Sentinel lymph node

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EARLY CANCER; FALSE NEGATIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MATHEMATICAL MODEL; NOMOGRAM; OCCULT CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SENTINEL LYMPH NODE BIOPSY; SURVIVAL TIME; THERAPY EFFECT; TUMOR LOCALIZATION;

ADENOCARCINOMA; AXILLA; BREAST NEOPLASMS; DIAGNOSTIC ERRORS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 79960957510     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.008     Document Type: Review

References (84)

1. Quiet C.A., Ferguson D.J., Weichselbaum R.R., et al. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995, 13(May (5)):1144-1151.
2. Giuliano A.E., Kirgan D.M., Guenther J.M., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220(September (3)):391-398. [discussion 398-401].
3. Cady B., Stone M.D., Schuler J.G., et al. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996, 131(March (3)):301-308.
4. Tabár L., Fagerberg G., Day N.E., et al. Breast cancer treatment and natural history: new insights from results of screening. Lancet 1992, 339(February (8790)):412-414.
5. Silverstein M.J., Gierson E.D., Waisman J.R., et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?. Cancer 1994, 73(February (3)):664-667.
6. Gould E.A., Winship T., Philbin P.H., Kerr H.H. Observations on a "sentinel node" in cancer of the parotid. Cancer 1960, 13(January-February):77-78.
7. McCready D., Holloway C., Shelley W., et al. Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg 2005, 48(June (3)):185-194.
8. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23(October (30)):7703-7720.
9. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000, 18(July (13)):2553-2559.
10. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349(August (6)):546-553.
11. Veronesi U., Paganelli G., Viale G., et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006, 7(December (12)):983-990.
12. Mansel R.E., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98(May (9)):599-609.
13. Chen J.J., Huang X.Y., Liu Z.B., et al. Sentinel node biopsy and quality of life measures in a Chinese population. Eur J Surg Oncol 2009, 35(September (9)):921-927.
14. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997, 349(June (9069)):1864-1867.
15. Giuliano A.E., Jones R.C., Brennan M., Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15(June (6)):2345-2350.
16. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998, 339(October (14)):941-946.
17. Fisher B., Redmond C., Fisher E.R., et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985, 312(March (11)):674-681.
18. White R.E., Vezeridis M.P., Konstadoulakis M., et al. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg 1996, 183(December (6)):575-582.
19. Orr R.K. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 1999, 6(January-February (1)):109-116.
20. Carlson R.W., Allred D.C., Anderson B.O., et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7(February (2)):122-192.
21. Straver M., Meijnen P., van Tienhoven G., et al. Current status of the EORTC 10981-22023 AMAROS trial-after mapping of the axilla radiotherapy or surgery. Eur J Cancer 2008, 6(April (Suppl. 7)):147.
22. Galimberti V. International Breast Cancer Study Group Trial of sentinel node biopsy. J Clin Oncol 2006, 24(January (1)):210-211.
23. White R.L., Wilke L.G. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 2004, 70(May (5)):420-424.
24. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10(December (10)):1140-1151.
25. Ozmen V., Karanlik H., Cabioglu N., et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 2006, 95(January (1)):1-6.
26. Barranger E., Coutant C., Flahault A., et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 2005, 91(May (2)):113-119.
27. Cody H.S., Van Zee K.J. Predicting nonsentinel node metastases in sentinel node-positive breast cancer: what have we learned, can we do better, and do we need to?. Ann Surg Oncol 2008, 15(November (11)):2998-3002.
28. Halsted W.S. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 1894, 20(November (5)):497-555.
29. Consensus statement: treatment of early-stage breast cancer National Institutes of Health Consensus Development Panel. J Natl Cancer Inst Monogr 1992, (11):1-5.
30. Petrek J.A., Blackwood M.M. Axillary dissection: current practice and technique. Curr Probl Surg 1995, 32(April (4)):257-323.
31. Schaapveld M., de Vries E.G., van der Graaf W.T., Otter R., de Vries J., Willemse P.H. The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association?. Ann Surg Oncol 2006, 13(April (4)):465-474.
32. Axelsson C.K., Düring M., Christiansen P.M., et al. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg 2009, 96(January (1)):40-46.
33. Axelsson C.K., Mouridsen H.T., Düring M., Møller S. Axillary staging during surgery for breast cancer. Br J Surg 2007, 94(March (3)):304-309.
34. Fisher B., Wolmark N., Bauer M., Redmond C., Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981, 152(June (6)):765-772.
35. Fisher B., Fisher E.R. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966, 122(April (4)):791-798.
36. Fisher B., Redmond C., Poisson R., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989, 320(March (13)):822-828.
37. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347(August (8)):567-575.
38. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337(October (14)):956-962.
39. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337(October (14)):949-955.
40. Quan M.L., McCready D. The evolution of lymph node assessment in breast cancer. J Surg Oncol 2009, 99(March (4)):194-198.
41. Krag D.N., Single R.M. Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003, 10(December (10)):1152-1159.
42. Polednak A.P. Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg 2003, 237(February (2)):163-167.
43. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(December (9503)):2087-2106.
44. Camp R.L., Rimm E.B., Rimm D.L. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000, 88(January (1)):108-113.
45. Vinh-Hung V., Burzykowski T., Cserni G., Voordeckers M., Van De Steene J., Storme G. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol 2003, 22(March (3)):697-704.
46. Miltenburg D.M., Miller C., Karamlou T.B., Brunicardi F.C. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999, 84(June (2)):138-142.
47. Kim T., Giuliano A.E., Lyman G.H. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006, 106(January (1)):4-16.
48. Tafra L., Lannin D.R., Swanson M.S., et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001, 233(January (1)):51-59.
49. McMasters K.M., Tuttle T.M., Carlson D.J., et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000, 18(July (13)):2560-2566.
50. Schrenk P., Rehberger W., Shamiyeh A., Wayand W. Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node?. J Surg Oncol 2002, 80(July (3)):130-136.
51. Zakaria S., Degnim A.C., Kleer C.G., et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough?. J Surg Oncol 2007, 96(December (7)):554-559.
52. Dabbs D.J., Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J 2004, 10(May-June (3)):186-189.
53. Viale G., Maiorano E., Mazzarol G., et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001, 92(September (6)):1378-1384.
54. Dowlatshahi K., Fan M., Snider H.C., Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997, 80(October (7)):1188-1197.
55. Cote R.J., Peterson H.F., Chaiwun B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999, 354(September (9182)):896-900.
56. Pargaonkar A.S., Beissner R.S., Snyder S., Speights V.O. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med 2003, 127(June (6)):701-705.
57. Abdul-Rasool S., Kidson S.H., Panieri E., et al. An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol 2006, 59(3):289-297.
58. Langer I., Guller U., Hsu-Schmitz S.F., et al. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 2009, 35(August (8)):805-813.
59. AJCC cancer staging manual 2010, Springer, New York, NY. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
60. Chagpar A.B., McMasters K.M. Treatment of sentinel node-positive breast cancer. Expert Rev Anticancer Ther 2006, 6(August (8)):1233-1239. [Review].
61. Yu J.C., Hsu G.C., Hsieh C.B., Sheu L.F., Chao T.Y. Prediction of metastasis to non-sentinel nodes by sentinel node status and primary tumor characteristics in primary breast cancer in Taiwan. World J Surg 2005, 29(July (7)):813-818. [discussion 818-9].
62. van Iterson V., Leidenius M., Krogerus L., von Smitten K. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res Treat 2003, 82(November (1)):39-45.
63. Grabau D. Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?. Surg Oncol 2008, 17(September (3)):211-217.
64. Cserni G., Gregori D., Merletti F., et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004, 91(October (10)):1245-1252.
65. Hwang R.F., Krishnamurthy S., Hunt K.K., et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003, 10(April (3)):248-254.
66. Pal A., Provenzano E., Duffy S.W., Pinder S.E., Purushotham A.D. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 2008, 95(March (3)):302-309.
67. Kohrt H.E., Olshen R.A., Bermas H.R., et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008, 8(March):66.
68. Smidt M.L., Kuster D.M., van der Wilt G.J., Thunnissen F.B., Van Zee K.J., Strobbe L.J. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands?. Ann Surg Oncol 2005, 12(December (12)):1066-1072. [Epub 2005 October 26].
69. Degnim A.C., Griffith K.A., Sabel M.S., et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003, 98(December (11)):2307-2315.
70. Houvenaeghel G., Nos C., Giard S., et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009, 35(July (7)):690-695. [Epub 2008 November 28].
71. Cserni G., Amendoeira I., Apostolikas N., et al. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 2003, 39(August (12)):1654-1667.
72. Poirier E., Sideris L., Dubé P., Drolet P., Meterissian S.H. Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the Canadian experience. Ann Surg Oncol 2008, 15(September (9)):2562-2567. [Epub 2008 July 10].
73. Houvenaeghel G., Nos C., Giard S., et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009, 35(July (7)):690-695.
74. Park J., Fey J.V., Naik A.M., Borgen P.I., Van Zee K.J., Cody H.S. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007, 245(March (3)):462-468.
75. Zgajnar J., Perhavec A., Hocevar M., et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol 2007, 96(December (7)):547-553.
76. Turner R.R., Chu K.U., Qi K., et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000, 89(August (3)):574-581.
77. Chu K.U., Turner R.R., Hansen N.M., Brennan M.B., Giuliano A.E. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 1999, 6(December (8)):756-761.
78. Alran S., De Rycke Y., Fourchotte V., et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007, 14(August (8)):2195-2201.
79. de Boer M., van Deurzen C.H., van Dijck J.A., et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361(August (7)):653-663.
80. Greco M., Agresti R., Cascinelli N., et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg 2000, 232(July (1)):1-7.
81. Bilimoria K.Y., Bentrem D.J., Hansen N.M., et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009, 27(June (18)):2946-2953. [Epub 2009 April 13].
82. Rutgers E.J. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol 2008, 26(February (5)):698-702.
83. Specht M.C., Kattan M.W., Gonen M., Fey J., Van Zee K.J. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005, 12(August (8)):654-659.
84. Grube B.J., Giuliano A.E. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001, 20(April-May (3)):230-237.